AXIM Biotechnologies Releases Preprint Manuscript Describing the Development of Company’S Rapid Point-Of-Care Test That Measures Covid-19 Neutralizing Antibodies
January 11, 2021 at 02:00 pm
Share
AXIM Biotechnologies, Inc. (“AXIM Biotech,” “AXIM” or “the Company”) announced that it has released a preprint of its manuscript describing the development of ImmunoPass, the Company’s rapid point-of-care test that semi-quantitatively measures levels of neutralizing antibodies to COVID-19. The manuscript is co-authored by several executives of AXIM’s subsidiary Sapphire Biotech, Inc., including Chief Clinical Officer Douglas F. Lake, Chief Scientific Officer Sergei Svarovsky and Chief Technology Officer Alim Seit-Nebi. Neutralizing antibodies are pivotal in halting the spread of the virus as they prevent the COVID-19 virus from infecting cells. As the world begins receiving the COVID-19 vaccine, recipients are reporting varying levels of neutralizing antibodies as each body responds differently to the vaccine. For this reason, it is important for recipients to measure their neutralizing antibodies regularly in order to know if and when it is time for a booster dose. AXIM’s ImmunoPass can serve as a convenient and effective testing option, as it has been proven to have 98% accuracy in detecting neutralizing antibodies using the benchmark of actual SARS-CoV-2 neutralization assays performed in a BSL3 laboratory. The advantages of AXIM’s ImmunoPass include that it uses only a single drop of blood, is smaller than the palm of a hand, highly portable, semi-quantitative, less expensive than a laboratory-based blood test, and can be used longitudinally to monitor increases and decreases in protective immunity after either natural infection or vaccine.
Axim Biotechnologies, Inc. is a vertically integrated research and development company. The Company is focused on improving the landscape for the diagnosis of ophthalmological conditions such as dry eye disease (DED) through rapid diagnostic tests. Its core competencies include development of rapid lateral flow immunoassays, reagents, and monoclonal antibody development for such assays. Its product categories include Eye Health, wherein the Company acquired two FDA cleared tests for dye eye disease and has internally developed a third assay; and SARS-CoV-2 neutralizing antibody tests. The Company is focused on developing a proprietary diagnostic platform that can be adapted to test for a variety of analytes including SARS-Cov-2, Lactoferrin, IgE, Lacritin, and MMP-9. Its platform capability can also be applied to rapid testing for vaccine candidates. Its platform can also be used to enable point-of-care detection for one or more cancers using a unique cancer biomarker, QSOX1-L.
AXIM Biotechnologies Releases Preprint Manuscript Describing the Development of Company’S Rapid Point-Of-Care Test That Measures Covid-19 Neutralizing Antibodies